Core Points - The article discusses the inclusion of 19 new drugs in the commercial health insurance innovation drug directory, highlighting their significance in the pharmaceutical market [10] - It emphasizes the advancements in CAR-T therapies and their impact on treating various cancers, particularly multiple myeloma and acute lymphoblastic leukemia [11][14][17] - The article also mentions the introduction of innovative drugs targeting Alzheimer's disease, showcasing their potential to change treatment paradigms [25][28] Group 1: New Drug Listings - A total of 19 new drugs have been added to the commercial health insurance innovation drug directory, including notable entries like Bristol-Myers Squibb's ipilimumab injection and Green Leaf Pharmaceutical's albituzumab injection [10] - The list includes various companies such as Pfizer, Novartis, and Jiangsu Hengrui Medicine, indicating a diverse range of pharmaceutical players involved [2][3][4] Group 2: CAR-T Therapies - The article highlights the global first approval of fully human CAR-T therapies, specifically targeting BCMA for treating relapsed or refractory multiple myeloma, with a five-year overall survival rate of 76.9% [12] - It mentions the efficacy of the CAR-T drug targeting GD2 for high-risk neuroblastoma, which has shown a real-world effectiveness rate exceeding 90% [14] - The introduction of dual-targeting CAR-T therapies, such as the one from Pfizer, is noted for significantly extending progression-free survival and overall survival in patients [15] Group 3: Alzheimer's Disease Treatments - The article discusses the launch of the first targeted drug for Alzheimer's disease in China, which aims to modify the disease's progression rather than just alleviate symptoms [25] - It highlights the significance of drugs like donanemab, which is the first to receive breakthrough therapy designation for Alzheimer's treatment, emphasizing its unique mechanism of action [28]

在国家政策对创新药的大力支持下，我国已有多款BTK抑制剂成功上市并纳入医保目录。截至目前，国 家医保目录纳入了多款BTK抑制剂，其中包括奥布替尼片、阿可替尼胶囊/马来酸阿可替尼片、匹妥布 替尼片等。今年，马来酸阿可替尼片用于CLL/SLLL（慢性淋巴细胞白血病/小淋巴细胞淋巴瘤）等适应 证被正式纳入医保，加之其他药物的成功续约，实现该类血液肿瘤多个疾病阶段的医保覆盖。 科技日报记者 张佳星 12月7日，国家医疗保障局正式公布2025年《国家基本医疗保险、生育保险和工伤保险药品目录》（以 下简称医保目录）。本次调整新增114种药品，目录内药品总数增至3253种，覆盖肿瘤、慢性病、罕见 病等多个治疗领域。肿瘤领域中的马来酸阿可替尼片等多款血液肿瘤新药被纳入。 哈尔滨血液病肿瘤研究所所长、中国临床肿瘤学会监事会监事长马军教授表示，对于慢性淋巴细胞白血 病、套细胞淋巴瘤等血液肿瘤患者来说，避免复发、延长无进展生存期是控制疾病关键。然而，淋巴瘤 临床诊疗长期面临着传统药物安全性不足、易复发、老年患者治疗棘手、与抗酸药等联用兼容性差等痛 点。 随着医学研究的深入发展，布鲁顿氏酪氨酸激酶（BTK）抑制剂等新型靶向药物问世， ...